IQVIA Collaborates with HealthCore to Advance Clinical Research Using Real-World Data
September 08 2021 - 8:00AM
Business Wire
IQVIA™ (NYSE: IQV) announces its strategic collaboration with
HealthCore, Inc., a leading real world research organization in the
United States, to advance real world evidence (RWE) studies with
increased quality and efficiency. RWE studies incorporate
innovative scientific methods with dynamic data from sources such
as electronic medical records, pharmacy and medical claims,
laboratory and genomics records, and patient-reported outcomes.
“IQVIA is excited to collaborate with HealthCore to enhance
novel research designs and the impact of real world studies,” said
Rob Kotchie, president, Real World Solutions at IQVIA. “Real world
evidence is playing an increasingly important role in healthcare
decision making. IQVIA is committed to enhancing evidence
generation with the goal of advancing patient health and clinical
outcomes.”
The IQVIA HealthCore agreement focuses on improving Real World
Data (RWD) breadth and depth, as well as research innovation. Most
HealthCore de-identified claims and clinical data have been
incorporated into the IQVIA PharMetrics® Plus data source,
resulting in a substantial patient volume increase. Voluntary
patient participation allows linkage to other supported data
sources, allowing a more complete view into the patient healthcare
experience. Large data sources are key to answering complex patient
research questions on topics such as clinical safety and
comparative effectiveness.
This innovative research collaboration will focus specifically
on real world studies such as external comparators, pragmatic
trials, and enriched studies. Enriched study types often combine
secondary data sources, along with primary data collection via
chart reviews and other forms of physician or opt-in patient data
collection, including patient-reported outcomes. With growing
regulatory acceptance of RWE in clinical trials, there is increased
interest in external comparator studies that utilize real world
data sources as comparison arms in single-arm trials. HealthCore’s
patient and physician networks support a more streamlined approach
to these studies through chart reviews and information
abstraction.
“We are so pleased to be working with IQVIA to enhance its data
environment and further our relationship through collaboration on
progressive research designs, such as synthetic control arm
studies, pragmatic clinical trials, decentralized clinical trials
and COVID-19 focused research,” said Mark Cziraky, president,
HealthCore.
About HealthCore, Inc.
HealthCore is finding evidence and truth at the core of
healthcare. We work with life sciences companies, government
agencies, payors, and collaborators on a broad range of research
services focused on informing key decision makers. As a wholly
owned, independently operating subsidiary of Anthem, Inc., we
utilize a powerful research ecosystem of expertise, relationships,
and data to generate the evidence needed to improve healthcare. To
learn more about HealthCore, visit www.HealthCore.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 74,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device, and pharmaceutical companies, medical researchers,
government agencies, payers, and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors, and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005304/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Nick Childs, IQVIA Investor Relations
(nicholas.childs@iqvia.com) +1.973.316.3828
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024